A practical reference on heptapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-03. Anything still debated is marked as such rather than presented as settled.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
| Property | Value | Notes |
|---|---|---|
| Primary route studied | Intranasal | Also examined parenterally in animal work |
| Reported plasma half-life | Minutes to tens of minutes | Values vary widely between reports |
| Main model systems | Rodent behavioural and cell assays | Human trials are few and small |
| Principal proposed targets | GABA-A receptor, GABA transaminase | Monoamine and neurotrophic pathways also reported |
| Evidence grade | Preliminary | Limited independent replication |
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
Reversed-phase high-performance liquid chromatography is the standard technique for estimating peptide purity. The result is a peak-area percentage, which describes how much of the detected material elutes as the main peak in one run. Mass spectrometry confirms the molecular mass and can reveal truncated, adducted, or otherwise modified species. Amino acid analysis or tandem mass spectrometry can address sequence fidelity when identity is in doubt. None of these measurements, taken alone, establishes that a sample is fit for any specific purpose.
== Evolutionary diversity == Most mammals have MHC variants similar to those of humans, who bear great allelic diversity, especially among the nine classical genes—seemingly due largely to gene duplication—though human MHC regions have many pseudogenes. The most diverse loci, namely HLA-A, HLA-B, and HLA-C, have roughly 6000, 7200, and 5800 known alleles, respectively. Many HLA alleles are ancient, sometimes of closer homology to a chimpanzee MHC alleles than to some other human alleles of the same gene. MHC allelic diversity has challenged evolutionary biologists for explanation. Most posit balancing selection (see polymorphism (biology)), which is any natural selection process whereby no single allele is absolutely most fit, such as frequency-dependent selection and heterozygote advantage. Pathogenic coevolution, as a type of balancing selection, posits that common alleles are under greatest pathogenic pressure, driving positive selection of uncommon alleles—moving targets, so to say, for pathogens. As pathogenic pressure on the previously common alleles decreases, their frequency in the population stabilizes, and remain circulating in a large population. Genetic drift is also a major driving force in some species. It is possible that the combined effects of some or all of these factors cause the genetic diversity. Beyond allelic polymorphism, the degree of evolutionary divergence between MHC alleles within individuals also influences immune function.
D-amino-acid dehydrogenase (EC 1.4.99.1, transferred to 1.4.99.6) is a bacterial enzyme that catalyses the oxidation of D-amino acids into their corresponding oxoacids. It contains both flavin and nonheme iron as cofactors. The enzyme has a very broad specificity and can act on most D-amino acids.
Alexander Stewart; Joseph Chi-Fung Ng; Gillian Wallis; Vasiliki Tsioligka; Franca Fraternali; Deborah K Dunn-Walters (18 March 2021). "Single-Cell Transcriptomic Analyses Define Distinct Peripheral B Cell Subsets and Discrete Development Pathways". Frontiers in Immunology. 12 602539. doi:10.3389/FIMMU.2021.602539. ISSN 1664-3224. PMC 8012727. PMID 33815362. Alexander Stewart; Emma Sinclair; Joseph Chi-Fung Ng; et al. (3 May 2022). "Pandemic, Epidemic, Endemic: B Cell Repertoire Analysis Reveals Unique Anti-Viral Responses to SARS-CoV-2, Ebola and Respiratory Syncytial Virus". Frontiers in Immunology. 13 807104. doi:10.3389/FIMMU.2022.807104. ISSN 1664-3224. PMC 9111746. PMID 35592326. Kate L Gibson; Yu-Chang Wu; Yvonne Barnett; et al. (5 November 2008). "B-cell diversity decreases in old age and is correlated with poor health status". Aging Cell. 8 (1): 18–25. doi:10.1111/J.1474-9726.2008.00443.X. ISSN 1474-9718. PMC 2667647. PMID 18986373. Yu-Chang Wu; David Kipling; Hui Sun Leong; Victoria Martin; Alexander A Ademokun; Deborah K Dunn-Walters (10 May 2010). "High-throughput immunoglobulin repertoire analysis distinguishes between human IgM memory and switched memory B-cell populations". Blood. 116 (7): 1070–1078. doi:10.1182/BLOOD-2010-03-275859. ISSN 0006-4971. PMC 2938129. PMID 20457872. D. K. Dunn-Walters; P. G. Isaacson; J. Spencer (1 August 1995). "Analysis of mutations in immunoglobulin heavy chain variable region genes of microdissected marginal zone (MGZ) B cells suggests that the MGZ of human spleen is a reservoir of memory B cells" (PDF).
Mistaken diagnoses are sometimes very serious problems as physicians concentrate on treatment after a diagnosis is reached, not retracing the diagnostic analysis. Ideally, diagnoses are always correct, but disease variations are such that they are sometimes in error. In the case of diabetes, the tests are very clear. If you do not have high blood glucose at times (e.g., when fasting), you should not be diagnosed as diabetic, though perhaps as "prediabetic". Every one has higher glucose levels for one or two hours after eating food which contains some types of carbohydrates. Dialysis providing kidney function artificially. This requires an artificial kidney (a dialysis machine) and relatively long periods hooked up to the machine every few days. It is not equivalent to a working kidney, but is sufficient to maintain life, sometimes for extended periods. Diastolic blood pressure See: Blood pressure. Diet plan See: Meal plan. Dietitian An expert in nutrition who helps people with special health needs plan the kinds and amounts of foods to eat. In the US, a registered dietitian (R.D.) has special training and experience. The health care team for diabetes should ideally include a dietitian, preferably an R.D. Dilated pupil examination A necessary part of an examination for diabetic eye disease. Special drops are used to enlarge the pupils, enabling the doctor to view the retina at the back of the eye for damage. See funduscopy. Distal sensory neuropathy See: Peripheral neuropathy.
Sources: en.wikipedia.org
The FMO method is implemented in GAMESS (US), ABINIT-MP, PAICS, and OpenFMO software packages, distributed free of charge. Fu, is a general open-source GUI that can generate input files for FMO. Another graphical user interface Facio developed by M. Suenaga has a very convenient specialised support of FMO (in addition to other features), with which an automatic fragmentation of molecular clusters, proteins, nucleotides, saccharides and any combination thereof (e.g., DNA and protein complexes in explicit solvent) can be done in a few minutes, and a manual fragmentation of solids and surfaces can be accomplished by clicking the bonds to be detached. Facio can also visualise results of FMO calculations, such as the pair interactions. (E – energy, G – gradient, H – Hessian; bold – can be used with PCM) GAMESS (US)
=== Setting === They Hunger takes place in a town called Rockwell, also called "the valley" by Deputy Jerry Hobbs. The location of the town is never revealed. The town is surrounded by many cliffs and canyons; many sections of the town are separated by tunnel systems. On the outskirts, there is "Rockwell Stud Bulls," a family-owned cattle company. One of the town's more notable landmarks is a large volcanic chasm, which appears to be the town's main tourist attraction dubbed "Devil's Rift." It also has a Stonehenge-type structure. The town has its own local radio station, BMRF Radio (a reference to the Black Mesa Research Facility from the Half-Life series).
=== Injectable amylin analogues === Amylin agonist analogues slow gastric emptying and suppress glucagon. They have all the incretins actions except stimulation of insulin secretion. As of 2007, pramlintide is the only clinically available amylin analogue. Like insulin, it is administered by subcutaneous injection. The most frequent and severe adverse effect of pramlintide is nausea, which occurs mostly at the beginning of treatment and gradually reduces. Typical reductions in A1C values are 0.5–1.0%.
== See also == Lists of sequenced genomes List of sequenced bacterial genomes List of sequenced archaeal genomes List of sequenced eukaryotic genomes List of sequenced mitochondrial genomes List of sequenced plastomes List of sequenced animal mitochondrial genomes List of sequenced fungi genomes List of sequenced fungi mitochondrial genomes List of sequenced plant genomes List of sequenced plant mitochondrial genomes List of sequenced protist genomes
== Further reading == Nakagawa, Allen S., LIMS implementation and management, Cambridge: Royal Society of Chemistry, 1994 Liscouski, Joe, Laboratory and Scientific Computing a Strategic Approach, John Wiley & Sons, New York, 1995 Gibbon, Gerst, "A Brief History of LIMS", Laboratory Automation and Information Management 1996, 32(1), 1-5 Myers, J. D.; Fox-Dobbs, C.; Laird, J.; Le, Dai; Reich, D.; Curtz, T., "Electronic laboratory notebooks for collaborative research", In Proceedings of the 5th International Workshops on Enabling Technologies: Infrastructure for Collaborative Enterprises (WET ICE'96) (WET-ICE '96) IEEE Computer Society, Washington, DC, USA, 1996, 47-. Paszko, Christine; Pugsley, Carol, "Considerations in selecting a laboratory information management system (LIMS)", American Laboratory, 2000, 32(18), 38-42 Paszko, Christine; Turner, Elizabeth; Hinton, Mary D., Laboratory Information Management Systems, Revised & Expanded.
Sources: en.wikipedia.org
== Chemistry == Retatrutide is a peptide with the following amino acid sequence YA¹QGTFTSDYSIL²LDKK⁴AQA¹AFIEYLLEGGPSSGAPPPS³ where letters with superscripted numbers refer to the following chemical modifications:
An etorphine antidote Large Animal Revivon contains mainly diprenorphine for animals and a human-specific naloxone-based antidote, which should be prepared prior to the etorphine. A 5–15 mg dose is enough to immobilise an African elephant and a 2–4 mg dose is enough to immobilise a black rhinoceros.
Olipudase alfa, sold under the brand name Xenpozyme, is a medication used for the treatment of non-central nervous system (CNS) manifestations of acid sphingomyelinase deficiency type A/B or type B. The most common side events include infections, infusion-related reactions, or gastrointestinal complaints (disease signs and symptoms in children). Historically referred to as Niemann-Pick disease types A (NPD A) and B (NPD B), acid sphingomyelinase deficiency is a genetic disorder. It belongs to the larger family of metabolic disorders called lysosomal storage diseases, in which fats build up within the parts of the body's cells that break down nutrients and other materials. This affects the way cells work and causes them to die, affecting normal functioning of tissues and organs. Acid sphingomyelinase deficiency is seriously debilitating and life-threatening since the build-up of fatty substances can cause brain damage and swelling of organs such as liver and spleen. Xenpozyme is the first acid sphingomyelinase deficiency-specific treatment. The replacement enzyme is produced by a method known as recombinant DNA technology: it is made by cells into which a gene (DNA) has been introduced, that enables them to produce the enzyme. Olipudase alfa was approved for medical use in Japan in March 2022, in the European Union in June 2022, and in the United States in August 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
=== One Health Approach === The One Health approach recognizes that human, animal, and environmental health are interconnected in the development and spread of antimicrobial resistance (AMR). Key strategies include:
Sources: en.wikipedia.org
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.
The peptide enters plasma rapidly and is broken down by ordinary proteases into amino acids and shorter fragments. Reported half-lives are short. Whether meaningful amounts of the intact molecule reach the brain is an open question.
Most clinical reports are small, published in Russian and not independently replicated. English-language reviews highlight the absence of large randomised trials. Conclusions about efficacy should be treated as provisional.
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter code. It combines the tetrapeptide tuftsin with a carboxyl-terminal Pro-Gly-Pro extension. This full sequence identifies the molecule more precisely than the research name.